Skip to main content
Skip to main content
Go to homepage

Multisystem Inflammatory Syndrome in Children Associated with COVID-19: A newly defined syndrome distinct from Kawasaki Disease


By Scott Pangonis, MD , Associate Director, Infectious Disease, Akron Children's Hospital, Akron, OH

Infectious Disease

More about Scott Pangonis, MD, MS, FAAP

Objectives (Educational Content) :

1. Identify the clinical, laboratory and imaging findings of multisystem inflammatory syndrome in children associated with COVID (MIS-C). 2. Describe the proposed pathophysiology of MIS-C. 3. Compare and contrast MIS-C and Kawasaki Disease. 4. Explain the interim guidance algorithm developed to identify and manage patients with MIS-C at Akron Children's Hospital.

Target Audience:

General pediatricians, family physicians, nurse practitioners, physician assistants, social workers, psychologists and nurses

Identified Gap:

New information regarding differences between MIS-C and Kawasaki Disease.

Estimated Time to Complete the Educational Activity:

1 hour

Expiration Date for CME Credit:


Method of Physician Participation in the Learning Process:

The learner will view the presentation, successfully complete a post-test and complete an activity evaluation.

Evaluation Methods:

All learners must successfully complete a post-test, as well as an activity evaluation, to claim CME credit.


Dr. Pangonis has indicated that he has no relevant financial interest in any pharmaceutical or medical device company and that this activity was developed independent of commercial interest.

Accreditation Statement:

Children’s Hospital Medical Center of Akron is accredited by the Ohio State Medical Association to provide continuing medical education for physicians.

CHMCA designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit TM.  Physicians should only claim the credit commensurate with the extent of their participation in the activity. 


1.Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York state. N Engl J Med. 2020;383(4):347-358. doi:10.1056/NEJMoa2021756

2.Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276-e288. doi:10.1016/S1473-3099(20)30651-4

3.Carter MJ, Shankar-Hari M, TibbySM. Paediatric Inflammatory Multisystem Syndrome Temporally-Associated with SARS-CoV-2 Infection: An Overview. Intensive Care Med. 2021;47(1):90-93. doi:10.1007/s00134-020-06273-2

4.Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. Arthritis Rheumatol. 2020;72(11):1791-1805. doi:10.1002/art.41454